A new Phase IV trial published in the European Medical Journal (EMJ) reveals that Shexiang Tongxin Dropping Pill (STDP), a Traditional Chinese Medicine (TCM), significantly improves coronary slow flow phenomenon (CSFP) in patients suffering from angina. CSFP is characterized by delayed coronary blood flow in the absence of obstructive coronary artery disease, leading to recurrent angina and reduced quality of life. The multicenter, randomized, controlled study evaluated the efficacy and safety of STDP in 200 adults, demonstrating significant reductions in corrected TIMI frame count (CTFC) in both the left anterior descending and left circumflex arteries for patients receiving STDP, indicating faster coronary flow. No major safety concerns were reported, suggesting a favorable safety profile. This research aligns with a broader body of evidence indicating the potential benefits of TCM in managing coronary artery disease and angina pectoris. Numerous systematic reviews and meta-analyses have found that TCM, often used as an adjunctive or complementary therapy alongside conventional Western medicine, can lead to improved clinical efficacy, reduced frequency and duration of angina attacks, and an enhanced quality of life for patients. Some studies also highlight TCM's role in improving microcirculation and preventing phenomena like no-reflow/slow-flow. While the EMJ article focuses on a specific TCM compound, the findings reinforce the growing acceptance of TCM as a viable option to improve cardiovascular health, especially for an audience in India where traditional medicine holds significant relevance. The European Medical Journal is an established, peer-reviewed, open-access medical journal, lending credibility to its published research.